MedPath

Prognostic value of minimal residual disease detection by multiparameter flow cytometry (EuroFlow method) in patients with multiple myeloma who underwent autologous stem cell transplantation: comparison with sequencing-based method

Not Applicable
Conditions
multiple myeloma
Registration Number
JPRN-UMIN000022238
Lead Sponsor
Kanazawa University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up continuing
Sex
All
Target Recruitment
66
Inclusion Criteria

Not provided

Exclusion Criteria

The patients who the physicians in charge judge to be inappropriate to participate in this trial.

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The correlation of MRD levels between BML-Flow and original EuroFlow methods.
Secondary Outcome Measures
NameTimeMethod
1)1-year PFS post-ASCT and 3-year PFS post-ASCT 2)1-year OS post-ASCT and 3-year OS post-ASCT 3)MRD negative rate in BM post-ASCT
© Copyright 2025. All Rights Reserved by MedPath